Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of$ 0.16. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.75%. A quarter ago, it was expected that this company would post a loss of$ 0.19 per share when it actually produced a loss of $0.20, delivering a surprise of -5.26%.Over the last four quarters, the company has surpas ...